EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early and Sustained Effects of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel

Leon Kircik, Edward Lain, Hilary Baldwin, Linda Stein Gold, Joshua A. Zeichner, Karol Wroblewski, Michael Gold, Valerie Callender,, Zoe Draelos, Julie Harper

SKIN The Journal of Cutaneous Medicine · 11.05.2026 · 10 (3) · s792

DOI: 10.25251/j35dfs02 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 11.05.2026. Verfasst von Leon Kircik und 9 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The combination of a topical antibiotic, retinoid, and benzoyl peroxide (BPO) is one of the most effective therapies for acne and has demonstrated greater efficacy versus monotherapy or dyads. However, it is unknown if triple-combinations impart rapid efficacy along with minimal tolerability issues, which may improve patient adherence. The only triple-combination acne topical, clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% (CAB) gel, has demonstrated efficacy and favorable tolerability in clinical trials. This pooled analysis assessed efficacy and safety of CAB versus vehicle following 4 and 12 weeks of treatment.

Methods

Pooled data from 4 double-blind, 12-week trials (phase 2, NCT03170388 and NCT04892706; phase 3, NCT04214639 and NCT04214652) of participants aged ≥9 years (≥12 years in NCT04892706) with moderate to severe acne were used to assess change from baseline in inflammatory/noninflammatory lesions and treatment success (percentage of participants achieving ≥2-grade reduction from baseline in Evaluator’s Global Severity Score and a score of 0 or 1 [clear/almost clear]). Treatment-emergent adverse events (TEAEs) and cutaneous safety/tolerability were also evaluated.

Results

Analyses were performed on data from 1115 participants randomized to CAB or vehicle (n=618 and n=497, respectively). At week 4, inflammatory lesions were reduced by >50% with CAB, with continued reductions of >75% at week 12, significantly greater than with vehicle (week 4, 53.8% vs 39.6%, respectively; week 12, 76.9% vs 52.9%; P

Zitieren

APA

Kircik, L., Lain, E., Baldwin, H., Gold, L. S., Zeichner, J. A., Wroblewski, K., Gold, M., Callender,, V., Draelos, Z., & Harper, J. (2026). Early and Sustained Effects of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel. SKIN The Journal of Cutaneous Medicine, 10(3), s792. https://doi.org/10.25251/j35dfs02

Vancouver

Kircik L, Lain E, Baldwin H, Gold LS, Zeichner JA, Wroblewski K, et al. Early and Sustained Effects of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel. SKIN The Journal of Cutaneous Medicine. 2026;10(3):s792. doi:10.25251/j35dfs02

BibTeX
@article{Kircik2026,
  author = {Kircik, Leon and Lain, Edward and Baldwin, Hilary and Gold, Linda Stein and Zeichner, Joshua A. and Wroblewski, Karol and Gold, Michael and Callender,, Valerie and Draelos, Zoe and Harper, Julie},
  title = {Early and Sustained Effects of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {3},
  pages = {s792},
  doi = {10.25251/j35dfs02}
}
Kostenlos starten →